ZEVRA THERAPEUTICS, INC. (ZVRA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 50M 100M 150M Q4 '14: 0 Q1 '15: 0 Q2 '15: 0 Q3 '15: 0 Q4 '15: 0 Q1 '16: 0 Q2 '19: 0 Q3 '19: 11.5M Q4 '19: 12.8M Q1 '20: 14.9M Q2 '20: 21.8M Q3 '20: 12.3M Q4 '20: 13.3M Q1 '21: 23.3M Q2 '21: 28.4M Q3 '21: 28.4M Q4 '21: 28.6M Q1 '22: 20.5M Q2 '22: 9.8M Q3 '22: 10.7M Q4 '22: 10.2M Q1 '23: 9.4M Q2 '23: 16.5M Q3 '23: 16.6M Q4 '23: 27.5M Q1 '24: 27.7M Q2 '24: 23.7M Q3 '24: 24.5M Q4 '24: 23.6M Q1 '25: 40.6M Q2 '25: 62M Q3 '25: 84.4M Q4 '25: 106.5M Q1 '26: 122.3M Q2 '26: 136.1M Q4 '15 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

0 50M 100M 150M Q4 '23: 24.3M Q1 '24: 23M Q2 '24: 14.6M Q3 '24: 11.7M Q4 '24: 9.8M Q1 '25: 25.5M Q2 '25: 38.1M Q3 '25: 62.7M Q4 '25: 85.9M Q1 '26: 102.5M Q2 '26: 128.4M Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-150M -100M -50M 0 50M 100M 150M Q3 '16: -33.9M Q4 '16: -37.5M Q1 '17: -37.9M Q2 '17: -36.8M Q3 '17: -36.1M Q4 '17: -33.4M Q1 '18: -40.8M Q2 '18: -46.4M Q3 '18: -54.8M Q4 '18: -55.9M Q1 '19: -52.5M Q2 '19: -46.4M Q3 '19: -25.2M Q4 '19: -20.3M Q1 '20: -12.7M Q2 '20: -2.4M Q3 '20: -6.8M Q4 '20: -5.6M Q1 '21: 5.1M Q2 '21: 8.4M Q3 '21: 7.4M Q4 '21: 7.7M Q1 '22: -1.1M Q2 '22: -31.7M Q3 '22: -36.1M Q4 '22: -42.6M Q1 '23: -53.5M Q2 '23: -35M Q3 '23: -43.8M Q4 '23: -49.6M Q1 '24: -57.3M Q2 '24: -74.8M Q3 '24: -86.7M Q4 '24: -87M Q1 '25: -71.9M Q2 '25: -119.1M Q3 '25: -87.7M Q4 '25: -62.9M Q1 '26: -5.4M Q2 '26: 82.4M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-150M -100M -50M 0 50M 100M 150M Q3 '16: -15.8M Q4 '16: -16.5M Q1 '17: -29.9M Q2 '17: -46.2M Q3 '17: -42.8M Q4 '17: -43.4M Q1 '18: -53.3M Q2 '18: -56.8M Q3 '18: -61.8M Q4 '18: -56.5M Q1 '19: -42.5M Q2 '19: -41.8M Q3 '19: -23.7M Q4 '19: -24.5M Q1 '20: -18M Q2 '20: -7.9M Q3 '20: -13.9M Q4 '20: -12.8M Q1 '21: -17.3M Q2 '21: -12M Q3 '21: -10.7M Q4 '21: -8.6M Q1 '22: -123K Q2 '22: -30.4M Q3 '22: -35.2M Q4 '22: -26.8M Q1 '23: -38.1M Q2 '23: -16.7M Q3 '23: -20.4M Q4 '23: -46M Q1 '24: -49.5M Q2 '24: -66.8M Q3 '24: -89.7M Q4 '24: -105.5M Q1 '25: -92M Q2 '25: 2.6M Q3 '25: 35.3M Q4 '25: 83.2M Q1 '26: 124.2M Q2 '26: 58.3M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

0 6M 12M 18M Q1 '22: 1.1M Q2 '22: 118K Q3 '22: 259K Q4 '22: 222K Q1 '23: 339K Q2 '23: 965K Q3 '23: 968K Q4 '23: 2.2M Q1 '24: 2.2M Q2 '24: 5.1M Q3 '24: 7.3M Q4 '24: 7.4M Q1 '25: 8.6M Q2 '25: 17.4M Q3 '25: 16.3M Q4 '25: 16.5M Q1 '26: 17M Q2 '26: 6.2M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q3 '16: -26.5M Q4 '16: -29.5M Q1 '17: -35.1M Q2 '17: -33.3M Q3 '17: -35.5M Q4 '17: -33.1M Q1 '18: -37.7M Q2 '18: -40.4M Q3 '18: -46.1M Q4 '18: -54.2M Q1 '19: -51.2M Q2 '19: -49.4M Q3 '19: -35.6M Q4 '19: -23.7M Q1 '20: -14.7M Q2 '20: -5.2M Q3 '20: -4M Q4 '20: -1.9M Q1 '21: -2.5M Q2 '21: 11.9M Q3 '21: 10.2M Q4 '21: 10.4M Q1 '22: 9.5M Q2 '22: -11.2M Q3 '22: -15.1M Q4 '22: -18.7M Q1 '23: -19.2M Q2 '23: -23.8M Q3 '23: -21.8M Q4 '23: -33.5M Q1 '24: -45.7M Q2 '24: -56.1M Q3 '24: -69.6M Q4 '24: -69.7M Q1 '25: -61.7M Q2 '25: -46.2M Q3 '25: -23.4M Q4 '25: -1.6M Q1 '26: 12.8M Q2 '26: 33.4M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-75M -50M -25M 0 25M 50M 75M Q1 '15: -17.8M Q2 '15: -20.2M Q3 '15: -21M Q4 '15: -20.4M Q1 '16: -20.3M Q2 '16: -23.5M Q3 '16: -27.1M Q4 '16: -30.1M Q1 '17: -35.8M Q2 '17: -33.9M Q3 '17: -35.8M Q4 '17: -33.3M Q3 '19: -35.7M Q4 '19: -23.8M Q1 '20: -14.7M Q2 '20: -5.2M Q3 '20: -4M Q4 '20: -2M Q1 '21: -2.5M Q2 '21: 11.8M Q3 '21: 10.1M Q4 '21: 10.3M Q1 '22: 9.4M Q2 '22: -11.3M Q3 '22: -15.2M Q4 '22: -18.8M Q1 '23: -19.3M Q2 '23: -23.9M Q3 '23: -22.1M Q4 '23: -33.8M Q1 '24: -45.9M Q2 '24: -56.3M Q3 '24: -69.6M Q4 '24: -69.7M Q1 '25: -61.8M Q2 '25: -46.5M Q3 '25: -24.2M Q4 '25: -2.4M Q1 '26: 12M Q2 '26: 32.6M Q1 '16 Q2 '17 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q2 '15: 12.2M Q2 '16: 15.4M Q2 '17: 14.6M Q2 '18: 16.5M Q3 '18: 16M Q2 '19: 28.4M Q3 '19: 31.7M Q2 '20: 3.9M Q3 '20: 4.4M Q1 '21: 19.1M Q2 '21: 29.2M Q3 '21: 35.2M Q1 '22: 34.5M Q2 '22: 34.4M Q3 '22: 34.5M Q1 '23: 34.5M Q2 '23: 33.9M Q3 '23: 34.7M Q1 '24: 41.8M Q2 '24: 41.9M Q3 '24: 47.8M Q1 '25: 54.1M Q2 '25: 56.3M Q3 '25: 56M Q1 '26: 60.2M Q2 '26: 61.3M Q2 '16 Q2 '19 Q1 '21 Q2 '22 Q3 '23 Q1 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q4 '14: -10.27 Q1 '15: -11.97 Q2 '15: -12.92 Q3 '15: -10.60 Q4 '15: -6.27 Q1 '16: -3.97 Q2 '16: -2.10 Q3 '16: -2.34 Q4 '16: -2.38 Q1 '17: -3.29 Q2 '17: -3.15 Q3 '17: -2.91 Q4 '17: -2.95 Q1 '18: -3.61 Q2 '18: -4.08 Q3 '18: -4.34 Q4 '18: -3.15 Q1 '19: -1.84 Q2 '19: -1.26 Q3 '19: -0.26 Q4 '20: -3.52 Q1 '22: 0.33 Q2 '22: 0.03 Q3 '22: -0.10 Q4 '22: -0.78 Q1 '23: -1.11 Q2 '23: -0.49 Q3 '23: -0.60 Q4 '23: -1.30 Q1 '24: -1.32 Q2 '24: -1.72 Q3 '24: -2.11 Q4 '24: -2.26 Q1 '25: -1.92 Q2 '25: -0.23 Q3 '25: 0.45 Q4 '25: 1.33 Q1 '26: 1.99 Q2 '26: 0.92 Q3 '15 Q4 '16 Q1 '18 Q2 '19 Q3 '22 Q4 '23 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.